CoChat

Discovery and validation of methylation markers for endometrial cancer

Open access
Wentzensen, Nicolas, Bakkum-Gamez, Jamie N., Killian, J. Keith, Sampson, Joshua, Guido, Richard, Glass, Andrew, Adams, Lisa, Luhn, Patricia, Brinton, Louise A., Rush, Brenda, d'Ambrosio, Lori, Gunja, Munira, Yang, Hannah P., Garcia-Closas, Montserrat, Lacey, James V., Lissowska, Jolanta, Podratz, Karl, Meltzer, Paul, Shridhar, Viji, Sherman, Mark E. · 2014 · International Journal of Cancer
Cited by 77

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

The prognosis of endometrial cancer is strongly associated with stage at diagnosis, suggesting that early detection may reduce mortality. Women who are diagnosed with endometrial carcinoma often have a lengthy history of vaginal bleeding, which offers an opportunity for early diagnosis and curative treatment. We performed DNA methylation profiling on population-based endometrial cancers to identify early detection biomarkers and replicated top candidates in two independent studies. We compared DNA methylation values of 1,500 probes representing 807 genes in 148 population-based endometrial carcinoma samples and 23 benign endometrial tissues. Markers were replicated in another set of 69 carcinomas and 40 benign tissues profiled on the same platform. Further replication was conducted in The Cancer Genome Atlas and in prospectively collected endometrial brushings from women with and without endometrial carcinomas. We identified 114 CpG sites showing methylation differences with p values of ≤ 10(-7) between endometrial carcinoma and normal endometrium. Eight genes (ADCYAP1, ASCL2, HS3ST2, HTR1B, MME, NPY and SOX1) were selected for further replication. Age-adjusted odds ratios for endometrial cancer ranged from 3.44 (95%-CI: 1.33-8.91) for ASCL2 to 18.61 (95%-CI: 5.50-62.97) for HTR1B. An area under the curve (AUC) of 0.93 was achieved for discriminating carcinoma from benign endometrium. Replication in The Cancer Genome Atlas and in endometrial brushings from an independent study confirmed the candidate markers. This study demonstrates that methylation markers may be used to evaluate women with abnormal vaginal bleeding to distinguish women with endometrial carcinoma from the majority of women without malignancy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.28843

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 33

  1. Wright, 2012, Contemporary management of endometrial cancer, Lancet, 379, 1352, 10.1016/S0140-6736(12)60442-5 · DOI · Paper page
  2. Kosary, 2007, SEER survival monograph: cancer survival among adults
  3. Lacey, 2008, Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan, Br J Cancer, 98, 45, 10.1038/sj.bjc.6604102 · DOI · Paper page
  4. Lacey, 2010, Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia, J Clin Oncol, 28, 788, 10.1200/JCO.2009.24.1315 · DOI · Paper page
  5. van Hanegem, 2011, Diagnostic evaluation of the endometrium in postmenopausal bleeding: an evidence-based approach, Maturitas, 68, 155, 10.1016/j.maturitas.2010.11.010 · DOI
  6. Sherman, 2008, Reproducibility of biopsy diagnoses of endometrial hyperplasia: evidence supporting a simplified classification, Int J Gynecol Pathol, 27, 318, 10.1097/PGP.0b013e3181659167 · doi:10.1097/pgp.0b013e3181659167
  7. Trimble, 2006, Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study, Cancer, 106, 812, 10.1002/cncr.21650 · DOI · Paper page
  8. Trimble, 2012, Management of endometrial precancers, Obstet Gynecol, 120, 1160, 10.1097/AOG.0b013e31826bb121 · DOI · Paper page
  9. Bach, 2002, Survival of blacks and whites after a cancer diagnosis, JAMA, 287, 2106, 10.1001/jama.287.16.2106 · DOI · Paper page
  10. Gallicchio, 2005, Fear of cancer among women undergoing hysterectomy for benign conditions, Psychosom Med, 67, 420, 10.1097/01.psy.0000160472.69303.56 · DOI
  11. Jiang, 2008, Application of DNA methylation biomarkers for endometrial cancer management, Expert Rev Mol Diagn, 8, 607, 10.1586/14737159.8.5.607 · DOI
  12. Kandoth, 2013, Integrated genomic characterization of endometrial carcinoma, Nature, 497, 67, 10.1038/nature12113 · DOI · Paper page
  13. Zhou, 2007, Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment, Gynecol Oncol, 107, 143, 10.1016/j.ygyno.2007.06.019 · DOI
  14. Brinton, 2007, Reproductive risk factors for endometrial cancer among Polish women, Br J Cancer, 96, 1450, 10.1038/sj.bjc.6603731 · DOI
  15. Kipp, 2008, Direct uterine sampling with the Tao brush sampler using a liquid-based preparation method for the detection of endometrial cancer and atypical hyperplasia: a feasibility study, Cancer, 114, 228, 10.1002/cncr.23636 · DOI
  16. Bibikova, 2009, GoldenGate assay for DNA methylation profiling, Methods Mol Biol, 507, 149, 10.1007/978-1-59745-522-0_12 · DOI · Paper page
  17. Killian, 2009, Large-scale profiling of archival lymph nodes reveals pervasive remodeling of the follicular lymphoma methylome, Cancer Res, 69, 758, 10.1158/0008-5472.CAN-08-2984 · DOI · Paper page
  18. Benjamini, 2001, Controlling the false discovery rate in behavior genetics research, Behav Brain Res, 125, 279, 10.1016/S0166-4328(01)00297-2 · DOI · Paper page
  19. Munoz, 2009, New imputation methods for missing data using quantiles, J Comput Appl Math, 232, 305, 10.1016/j.cam.2009.06.011 · DOI
  20. Simon, 2007, Analysis of gene expression data using BRB-ArrayTools, Cancer Inform, 3, 11, 10.1177/117693510700300022 · DOI · Paper page
  21. Nieminen, 2009, Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia, Clin Cancer Res, 15, 5772, 10.1158/1078-0432.CCR-09-0506 · DOI
  22. Shivapurkar, 2007, Evaluation of candidate methylation markers to detect cervical neoplasia, Gynecol Oncol, 107, 549, 10.1016/j.ygyno.2007.08.057 · DOI
  23. Takai, 2001, Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis, Oncogene, 20, 7505, 10.1038/sj.onc.1204940 · DOI
  24. Archer, 2010, High-throughput assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCV-associated hepatocellular carcinoma, Mol Genet Genom, 283, 341, 10.1007/s00438-010-0522-y · DOI
  25. Sousa, 2011, Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients, Cell Stem Cell, 9, 476, 10.1016/j.stem.2011.10.008 · DOI · Paper page
  26. Cohen, 2010, Pituitary adenylyl cyclase activating polypeptide inhibits gli1 gene expression and proliferation in primary medulloblastoma derived tumorsphere cultures, BMC Cancer, 10, 676, 10.1186/1471-2407-10-676 · DOI
  27. Zhang, 2011, The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer, Pharmacol Ther, 131, 91, 10.1016/j.pharmthera.2011.03.011 · DOI · Paper page
  28. Zhang, 2012, NPY modulates PYY function in the regulation of energy balance and glucose homeostasis, Diabetes Obes Metab, 14, 727, 10.1111/j.1463-1326.2012.01592.x · DOI
  29. Torres, 2012, Risk factors for developing endometrial cancer after benign endometrial sampling, Obstet Gynecol, 120, 998, 10.1097/AOG.0b013e31826b9fef · DOI
  30. Evans, 2011, Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006, Br J Cancer, 104, 1505, 10.1038/bjc.2011.68 · DOI · Paper page
  31. Widschwendter, 2004, Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors, Clin Cancer Res, 10, 3396, 10.1158/1078-0432.CCR-03-0143 · DOI
  32. Wu, 2000, Endometrial brush biopsy (Tao brush). Histologic diagnosis of 200 cases with complementary cytology: an accurate sampling technique for the detection of endometrial abnormalities, Am J Clin Pathol, 114, 412, 10.1093/ajcp/114.3.412 · DOI
  33. Wentzensen, 2013, From differences in means between cases and controls to risk stratification: a business plan for biomarker development, Cancer Discov, 3, 148, 10.1158/2159-8290.CD-12-0196 · DOI

Cited by

Metadata

Authors
Wentzensen, N., Bakkum-Gamez, J. N., Killian, J. K., Sampson, J., Guido, R., Glass, A., Adams, L., Luhn, P., Brinton, L. A., Rush, B., d'Ambrosio, L., Gunja, M., Yang, H. P., Garcia-Closas, M., Lacey, J. V., Lissowska, J., Podratz, K., Meltzer, P., Shridhar, V., & Sherman, M. E.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2014-03-31
Volume
135
Issue
8
Pages
1860-1868
ISSN
0020-7136 (ISSN-L)
OpenAlex
W1607675287
Cited by
77
References
3
FWCI
2.31
Type
journal article
Language
en
Open access
green
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 519 d)
Funders
National Institutes of Health (ZIA CP010126-14)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.